Abstract 449P
Background
Improved cancer survival rates have escalated the demand for sustainable supportive care for survivors. Nasopharyngeal cancer (NPC) survivors often grapple with lasting radiation side effects. The M. D. Anderson Symptom Inventory - Head & Neck Module - Chinese version (MDASI-HN-C) has previously been validated for NPC patients undergoing radiation therapy (RT), but not for survivors. This study aims to psychometrically validate the MDASI-HN-C for NPC survivors.
Methods
In this single-centre cross-sectional study, 200 NPC survivors who completed RT with or without chemotherapy between three and 120 months were surveyed. The internal consistency reliability, convergent, and construct validity of the MDASI-HN-C were evaluated using Cronbach’s alpha (α) test, Pearson’s correlation (r), and exploratory factor analysis (EFA), respectively.
Results
All three subscales of the MDASI-HN-C exhibited strong internal consistency, with α ranging from 0.855 to 0.911. The MDASI-HN-C subscales were negatively correlated with the total score (r = -0.538 to -0.612; all p < 0.001), physical (r = -0.679 to -0.787; all p < 0.001), emotional (r = -0.536 to -0.625; all p < 0.001), functional (r = -0.307 to -0.390; all p < 0.001), and HN-specific (r = -0.587 to -0.616; all p < 0.001) domains of the Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN) scale. No correlations were identified between any subscales and the social/family domain. The MDASI-HN-C subscales were also positively correlated with the total score of the Cancer Survivors’ Unmet Needs Measure (CaSUN) (r = 0.414 to 0.468; all p < 0.001). Two factors for the 13 core items were identified by EFA, while only one factor each was found for the HN-specific and interference items. Noteworthily, open-ended responses indicated significant concerns about hearing loss and tinnitus among NPC survivors.
Conclusions
The MDASI-HN-C is a robust tool with satisfactory psychometric properties for assessing symptom burden among NPC survivors. The inclusion of 'hearing problems' as an additional item would enhance its applicability by capturing sensorial disturbances that significantly affect this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract